3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
5
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Neoplasms
7
Multiple Myeloma
7
Lymphoma
7
Carcinoma, Non-Small-Cell Lung
6
Lymphoma, T-Cell, Cutaneous
4
Mycosis Fungoides
3
Sezary Syndrome
2
Recurrence
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Vascular Diseases
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Interventions
10-propargyl-10-deazaaminopterin
6
Brentuximab Vedotin
5
romidepsin
3
Vitamin B 12
3
Rituximab
3
Folic Acid
3
Cyclophosphamide
3
tenalisib
2
cobomarsen
2
belinostat
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Doxorubicin
2
zanubrutinib
1
zanolimumab
1
venetoclax
1
tislelizumab
1
quisinostat
1
pembrolizumab
1
mogamulizumab
1
fostamatinib
1
forodesine
1
fludarabine
1
enzastaurin
1
enzalutamide
1
duvelisib
1
denileukin diftitox
1
darinaparsin
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell
×
Vorinostat
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts